CM
MannKind Corp Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Afrezza (insulin human) Inhalation Powder | Type 1 & Type 2 Diabetes (Adults) | Approved |
| Tyvaso DPI (treprostinil) Inhalation Powder | Pulmonary Arterial Hypertension (PAH) & PH associated with ILD | Approved |
| Clofazimine Inhalation Powder | Nontuberculous Mycobacterial (NTM) Lung Disease | Phase 2 |
| Treprostinil Inhalation Powder | PH associated with COPD (PH-COPD) | Phase 2 |
| Technosphere-enabled formulations | Various (e.g., GLP-1 agonists) | Preclinical |
Leadership Team at MannKind Corp
ME
Michael E. Castagna
Chief Executive Officer
SB
Steven B. Binder
Chief Financial Officer
DP
David P. Thomson
Chief Scientific Officer
JS
James S. Shannon
Chief Medical Officer
JK
Jennifer K. Sanfilippo
Chief Legal Officer & Corporate Secretary
AE
Alfred E. Mann
Founder & Former Chairman
RJ
Raymond J. Land
Senior Vice President, Chief Accounting Officer
TB
Tyler Blomenkamp
Senior Vice President, Commercial Operations
AL
Andrew Lee
Senior Vice President, Technical Operations
KK
Kent Kresa
Chairman of the Board